{
    "id": "0380",
    "question": "A 70-year-old obese male presents to the emergency department with shortness of breath and cough of sudden onset. The patient states that his symptoms came on while he was sleeping. The patient has a past medical history of type II diabetes and is currently taking lisinopril, metformin, insulin, and fish oil. On physical exam, you note bipedal edema and jugular venous distention (JVD). An EKG and chest radiographs are obtained (Figures A and B). The patient is started on BIPAP and medical therapy and his symptoms improve rapidly. Lab values are as follows.\n\nSerum:\nNa+: 137 mEq/L\nK+: 3.2 mEq/L\nCl-: 100 mEq/L\nHCO3-: 31 mEq/L\nBUN: 20 mg/dL\nGlucose: 120 mg/dL\nCreatinine: 1.2 mg/dL\nCa2+: 10.9 mg/dL\n\nWhich of the following is the best explanation of this patient's current presentation?",
    "options": {
        "A": "Furosemide",
        "B": "Hydrochlorothiazide",
        "C": "Renal tubular acidosis type II",
        "D": "Renal tubular acidosis type IV"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine the best explanation for the patient's current presentation, we need to analyze the provided information and the patient's symptoms. The patient presents with shortness of breath, cough of sudden onset, bipedal edema, and jugular venous distention (JVD). These symptoms are indicative of heart failure, which can be caused by various factors including renal tubular acidosis (RTA). Let's evaluate the provided options: A. Furosemide: Furosemide is a loop diuretic that can cause hypokalemia (low potassium levels) and metabolic alkalosis (elevated bicarbonate levels), which is consistent with the patient's lab values (K+ 3.2 mEq/L, HCO3- 31 mEq/L). However, the patient's symptoms of shortness of breath and cough are not typical of furosemide toxicity. B. Hydrochlorothiazide: Hydrochlorothiazide is a thiazide diuretic that can cause hypokalemia and metabolic acidosis (decreased bicarbonate levels), which is not consistent with the patient's lab values (HCO3- 31 mEq/L). Additionally, thiazide diuretics can cause hypovolemia, which is not supported by the patient's edema. C. Renal tubular acidosis type II: RTA type II, also known as distal RTA, is characterized by a failure of the distal tubules to acidify the urine, leading to metabolic acidosis and hypokalemia. The patient's lab values (HCO3- 31 mEq/L, K+ 3.2 mEq/L) and symptoms (edema, JVD) are consistent with RTA type II. D. Renal tubular acidosis type IV: RTA type IV, also known as proximal RTA, is characterized by a failure of the proximal tubules to reabsorb bicarbonate, leading to metabolic acidosis and hyperkalemia. This is not consistent with the patient's lab values (HCO3- 31 mEq/L, K+ 3.2 mEq/L) and symptoms (edema, JVD). Based on the analysis, the best explanation for the patient's current presentation is C. Renal tubular acidosis type II (distal RTA). This condition can cause hypokalemia, metabolic alkalosis, and edema, which are all consistent with the patient's symptoms and lab values.\", \"answer_choice\": \"C\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_3617",
            "title": "InternalMed_Harrison",
            "content": "A 63-year-old man was admitted to the intensive care unit (ICU) with a severe aspiration pneumonia. Past medical history included schizophrenia, for which he required institutional care; treatment had included neuroleptics and intermittent lithium, the latter restarted 6 months before admission. The patient was treated with antibiotics and intubated for several days, with the development of polyuria (3\u20135 L/d), hypernatremia, and acute renal insufficiency; the peak plasma Na+ concentration was 156 meq/L, and peak creatinine was 2.6 mg/dL. Urine osmolality was measured once and reported as 157 mOsm/kg, with a coincident plasma osmolality of 318 mOsm/kg. Lithium was stopped on admission to the ICU. On physical examination, the patient was alert, extubated, and thirsty. Weight was 97.5 kg. Urine output for the previous 24 h had been 3.4 L, with an IV intake of 2 L/d of D5W."
        },
        {
            "id": "InternalMed_Harrison_3597",
            "title": "InternalMed_Harrison",
            "content": "Fluid and Electrolyte Imbalances and Acid-Base Disturbances: Case Examples David B. Mount, Thomas D. DuBose, Jr. CASE 1 64e A 23-year-old woman was admitted with a 3-day history of fever, cough productive of blood-tinged sputum, confusion, and orthostasis. Past medical history included type 1 diabetes mellitus. A physical examination in the emergency department indicated postural hypo-tension, tachycardia, and Kussmaul respiration. The breath was noted to smell of \u201cacetone.\u201d Examination of the thorax suggested consolidation in the right lower lobe. Sodium 130 meq/L Potassium 5.0 meq/L Chloride 96 meq/L CO2 14 meq/L Blood urea nitrogen (BUN) 20 mg/dL Creatinine 1.3 mg/dL Glucose 450 mg/dL Pneumonic infiltrate, right lower lobe The diagnosis of the acid-base disorder should proceed in a stepwise fashion: 1. The normal anion gap (AG) is 8\u201310 meq/L, but in this case, the AG is elevated (20 meq/L). Therefore, the change in AG (\u0394AG) = ~10 meq/L. 2."
        },
        {
            "id": "InternalMed_Harrison_3630",
            "title": "InternalMed_Harrison",
            "content": "A 78-year-old man was admitted with pneumonia and hyponatremia. Plasma Na+ concentration was initially 129 meq/L, decreasing within 3 days to 118\u2013120 meq/L despite fluid restriction to 1 L/d. A chest computed tomography (CT) revealed a right 2.8 \u00d7 1.6 cm infrahilar mass and postobstructive pneumonia. The patient was an active smoker. Past medical history was notable for laryngeal carcinoma treated 15 years prior with radiation therapy, renal cell carcinoma, peripheral vascular disease, and hypothyroidism. On review of systems, he denied headache, nausea, and vomiting. He had chronic hip pain, managed with acetaminophen with codeine. Other medications included cilostazol, amoxicillin/clavulanate, digoxin, diltiazem, and thyroxine. He was euvolemic on examination, with no lymphadenopathy and a normal chest examination. Na+ 120 K+ 4.3 Cl\u2212 89 HCO3\u2212 23 BUN 8 Creat 1.0 Glu 93 Alb 3.1 Ca 8.9 Phos 2.8 Mg 2.0 Plasma osm 248 mOsm/kg Cortisol 25 \u03bcg/dL TSH 2.6 Uric acid 2.7 mg/dL"
        },
        {
            "id": "Pharmacology_Katzung_4629",
            "title": "Pharmacology_Katzung",
            "content": "A 66-year-old obese Caucasian man presented to an academic Diabetes Center for advice regarding his diabetes treatment. His diabetes was diagnosed 10 years previously on routine testing. He was initially given metformin but when his control deteriorated, the metformin was stopped and insulin treatment initiated. The patient was taking 50 units of insulin glargine and an average of 25 units of insulin aspartate pre-meals. He had never seen a diabetes educator or a dietitian. He was checking his glucose levels 4 times a day. He was smoking half a pack of cigarettes a day. On examination, his weight was 132 kg (BMI 39.5); blood pressure 145/71; and signs of mild peripheral neuropathy were present. Laboratory tests noted an HbA1c value of 8.1%, urine albumin 3007 mg/g creatinine (normal <30), serum creatinine 0.86 mg/dL (0.61\u20131.24), total choles-terol 128 mg/dL, triglycerides 86 mg/dL, HDL cholesterol 38 mg/dL, and LDL cholesterol 73 mg/dL (on atorvastatin 40 mg daily). How would you"
        },
        {
            "id": "InternalMed_Harrison_3642",
            "title": "InternalMed_Harrison",
            "content": "The plasma Na+ concentration on admission was 113 meq/L, with a creatinine of 2.35 (Table 64e-1). At hospital hour 7, the plasma Na+ concentration was 120 meq/L, potassium 5.4 meq/L, chloride 90 64e-5 meq/L, bicarbonate 22 meq/L, BUN 32 mg/dL, creatinine 2.02 mg/dL, glucose 89 mg/dL, total protein 5.0, and albumin 1.9. The hematocrit was 33.9, white count 7.6, and platelets 405. A morning cortisol was 19.5, with thyroid-stimulating hormone (TSH) of 1.7. The patient was treated with 1 \u03bcg of intravenous DDAVP, along with 75 mL/h of intravenous half-normal saline. After the plasma Na+ concentration dropped to 116 meq/L, intravenous fluid was switched to normal saline at the same infusion rate. The subsequent results are shown in Table 64e-1."
        },
        {
            "id": "InternalMed_Harrison_3685",
            "title": "InternalMed_Harrison",
            "content": "A stuporous 22-year-old man was admitted with a history of behaving strangely. His friends indicated he experienced recent emotional problems stemming from a failed relationship and had threatened suicide. There was a history of alcohol abuse, but his friends were unaware of recent alcohol consumption. The patient was obtunded on admission, with no evident focal neurologic deficits. The remainder of the physical examination was unremarkable. Na+ 140 meq/L K+ 5 meq/L Cl\u2212 95 meq/L HCO3\u2212 10 meq/L Glucose 125 mg/dL BUN 15 mg/dL Creatinine 0.9 mg/dL Ionized calcium 4.0 mg/dL Plasma osmolality 325 mOsm kg/H2O Urinalysis revealed crystalluria, with a mixture of envelope-shaped and needle-shaped crystals."
        },
        {
            "id": "InternalMed_Harrison_27954",
            "title": "InternalMed_Harrison",
            "content": "3. Assess: Serum electrolytes (K+, Na+, Mg2+, Cl\u2212, bicarbonate, phosphate) Acid-base status\u2014pH, HCO3\u2212, PCO2, \u03b2-hydroxybutyrate Renal function (creatinine, urine output) 4. Replace fluids: 2\u20133 L of 0.9% saline over first 1\u20133 h (10\u201320 mL/kg per hour); subsequently, 0.45% saline at 250\u2013500 mL/h; change to 5% glucose and 0.45% saline at 150\u2013250 mL/h when plasma glucose reaches 250 mg/dL (13.9 mmol/L). 5. Administer short-acting insulin: IV (0.1 units/kg), then 0.1 units/kg per hour by continuous IV infusion; increase twoto threefold if no response by 2\u20134 h. If the initial serum potassium is <3.3 mmol/L (3.3 meq/L), do not administer insulin until the potassium is corrected. 6. Assess patient: What precipitated the episode (noncompliance, infection, trauma, pregnancy, infarction, cocaine)? Initiate appropriate workup for precipitating event (cultures, CXR, ECG). 7."
        },
        {
            "id": "InternalMed_Harrison_3631",
            "title": "InternalMed_Harrison",
            "content": "Na+ 120 K+ 4.3 Cl\u2212 89 HCO3\u2212 23 BUN 8 Creat 1.0 Glu 93 Alb 3.1 Ca 8.9 Phos 2.8 Mg 2.0 Plasma osm 248 mOsm/kg Cortisol 25 \u03bcg/dL TSH 2.6 Uric acid 2.7 mg/dL Urine: Na+ 97 K+ 22 Cl\u2212 86 Osm 597 The patient was treated with furosemide, 20 mg PO bid, and salt tablets. The plasma Na+ concentration increased to 129 meq/L with this therapy; however, the patient developed orthostatic hypotension and dizziness. He was started on demeclocycline, 600 mg PO in the morning and 300 mg in the evening, just before discharge from hospital. Plasma Na+ concentration increased to 140 meq/L with a BUN of 23 and creatinine of 1.4, at which point demeclocycline was reduced to 300 mg PO bid. Bronchoscopic biopsy eventually showed small-cell lung cancer; the patient declined chemotherapy and was admitted to hospice. What factors contributed to this patient\u2019s hyponatremia? What are the therapeutic options?"
        },
        {
            "id": "InternalMed_Harrison_3656",
            "title": "InternalMed_Harrison",
            "content": "A 32-year-old man was admitted to the hospital with weakness and hypokalemia. The patient had been very healthy until 2 months previously when he developed intermittent leg weakness. His review of systems was otherwise negative. He denied drug or laxative abuse and was on no medications. Past medical history was unremarkable, with no history of neuromuscular disease. Family history was notable for a sister with thyroid disease. Physical examination was notable only for reduced deep tendon reflexes. Sodium 139 143 meq/L Potassium 2.0 3.8 meq/L Chloride 105 107 meq/L Bicarbonate 26 29 meq/L BUN 11 16 mg/dL Creatinine 0.6 1.0 mg/dL Calcium 8.8 8.8 mg/dL Phosphate 1.2 mg/dL Albumin 3.8 meq/L TSH 0.08 \u03bcIU/L (normal 0.2\u20135.39) Free T4 41 pmol/L (normal 10\u201327)"
        },
        {
            "id": "Pharmacology_Katzung_1490",
            "title": "Pharmacology_Katzung",
            "content": "Ramin Sam, MD, Harlan E. Ives, MD, PhD, & David Pearce, MD A 65-year-old man has a history of diabetes and chronic kidney disease with baseline creatinine of 2.2 mg/dL. Despite five different antihypertensive drugs, his clinic blood pres-sure is 176/92 mm Hg; he has mild dyspnea on exertion and 2\u20133+ edema on exam. He has been taking furosemide 80 mg twice a day for 1 year now. At the clinic visit, hydrochlorothi-azide 25 mg daily is added for better blood pressure control and also to treat symptoms and signs of fluid overload. Two weeks later, the patient presents to the emergency depart-ment with symptoms of weakness, anorexia, and generalized malaise. His blood pressure is now 91/58 mm Hg, and he has lost 15 kg in 2 weeks. His laboratory tests are signifi-cant for a serum creatinine of 10.8 mg/dL. What has led to the acute kidney injury? What is the reason for the weight loss? What precautions could have been taken to avoid this hospitalization?"
        },
        {
            "id": "InternalMed_Harrison_27761",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 417-3 Relationship of diabetes-specific complication and glucose tolerance. This figure shows the incidence of retinopathy in Pima Indians as a function of the fasting plasma glucose (FPG), the 2-h plasma glucose after a 75-g oral glucose challenge (2-h PG), or the hemoglobin A1c (HbA1c). Note that the incidence of retinopathy greatly increases at a fasting plasma glucose >116 mg/dL, a 2-h plasma glucose of 185 mg/dL, or an HbA1c >6.5%. (Blood glucose values are shown in mg/dL; to convert to mmol/L, divide value by 18.) (Copyright 2002, American Diabetes Association. From Diabetes Care 25[Suppl 1]: S5\u2013S20, 2002.) 70 89 93 97 100 105 109 116 136 226 38 94 106 116 126 138 156 185 244 364 3.4 4.8 5.0 5.2 5.3 5.5 5.7 6.0 6.7 9.5 concentration \u226511.1 mmol/L (200 mg/dL) accompanied by classic 2401 symptoms of DM (polyuria, polydipsia, weight loss) is also sufficient for the diagnosis of DM (Table 417-2)."
        },
        {
            "id": "Pharmacology_Katzung_4656",
            "title": "Pharmacology_Katzung",
            "content": "If the fasting plasma glucose level is less than 126 mg/dL (7 mMol/L) but diabetes is nonetheless suspected, then a standardized oral glucose tolerance test may be done (Table 41\u20134). The patient should eat nothing after midnight prior to the test day. On the morning of the test, adults are then given 75 g of glucose in 300 mL of water; children are given 1.75 g of glucose per kilogram of ideal body weight. The glucose load is consumed within 5 minutes. Blood samples for plasma glucose are obtained at 0 and 120 minutes after ingestion of glucose. An oral glucose tolerance test is normal if the fasting venous plasma glucose value is less than 100 mg/dL (5.6 mmol/L) and the 2-hour value falls below 140 mg/dL (7.8 mmol/L). A fasting value of 126 mg/dL (7 mmol/L) or higher or a 2-hour value of greater than 200 mg/dL (11.1 mmol/L) is diagnostic of diabetes mellitus. Patients with 2-hour value of 140\u2013199 mg/dL (7.8\u201311.1 mmol/L) have impaired glucose tolerance."
        },
        {
            "id": "InternalMed_Harrison_3650",
            "title": "InternalMed_Harrison",
            "content": "A 44-year-old woman was referred from a local hospital after presenting with flaccid paralysis. Severe hypokalemia was documented (2.0 meq/L), and an infusion containing KCl was initiated. PART 2 Cardinal Manifestations and Presentation of Diseases Sodium 140 meq/L Potassium 2.6 meq/L Chloride 115 meq/L Bicarbonate 15 meq/L Anion gap 10 meq/L BUN 22 mg/dL Creatinine 1.4 mg/dL pH 7.32 U PaCO2 30 mmHg HCO3\u2212 15 meq/L Rheumatoid factor positive, anti-Ro/SS-A positive, and anti-La/SS-B positive pH = 6.0, normal sediment without white or red blood cell casts and no bacteria. The urine protein-to-creatinine ratio was 0.150 g/g. Urinary electrolyte values were: Na+ 35, K+ 40, Cl\u2212 18 meq/L. Therefore, the urine anion gap was positive, indicating low urine NH4+ excretion."
        },
        {
            "id": "Pharmacology_Katzung_7019",
            "title": "Pharmacology_Katzung",
            "content": "Her social history is significant for alcohol use (three to four glasses of wine/night). Her vital signs include the following: temperature 99.8\u00b0F, blood pressure 132/64 mm Hg, pulse 78 bpm, and respiratory rate 15/min. On physical examination, she had left upper abdominal tenderness with evidence of hepatomegaly and mild scleral icterus. Laboratory data revealed the following: alanine aminotransferase, 527 IU/L (normal 10\u201335 IU/L); aspartate aminotransferase, 425 IU/L (normal < 35 IU/L); and bilirubin, 2.9 mg/dL (normal 0.1\u20130.3 mg/dL). What medications do OTC cold and flu preparations typically contain? Which of the OTC medications might have contrib-uted to the patient\u2019s current symptoms? KH, a 55-year-old woman, presents to the emergency department with nausea, vomiting, and complaints of new-onset flu symptoms over the past several days. Her past medical history is significant for allergic rhinitis and chronic lower back pain secondary to a work-related fall 2 years ago. Her"
        },
        {
            "id": "Pharmacology_Katzung_1006",
            "title": "Pharmacology_Katzung",
            "content": "Neal L. Benowitz, MD A 35-year-old man presents with a blood pressure of 150/95 mm Hg. He has been generally healthy, is sedentary, drinks several cocktails per day, and does not smoke cigarettes. He has a family history of hypertension, and his father died of a myocardial infarction at age 55. Physical examination is remarkable only for moderate obesity. Total cholesterol is 220, and high-density lipoprotein (HDL) cholesterol level is 40 mg/dL. Fasting glucose is 105 mg/dL. Chest X-ray is normal. Electrocardiogram shows left ven-tricular enlargement. How would you treat this patient?"
        },
        {
            "id": "InternalMed_Harrison_3664",
            "title": "InternalMed_Harrison",
            "content": "A 66-year-old man was admitted to hospital with a plasma K+ concentration of 1.7 meq/L and profound weakness. The patient had noted progressive weakness over several days, to the point that he was unable to rise from bed. Past medical history was notable for small-cell lung cancer with metastases to brain, liver, and adrenals. The patient had been treated with one cycle of cisplatin/etoposide 1 year before this admission, which was complicated by acute kidney injury (peak creatinine of 5, with residual chronic kidney disease), and three subsequent cycles of cyclophosphamide/doxorubicin/vincristine, in addition to 15 treatments with whole-brain radiation. On physical examination, the patient was jaundiced. Blood pressure was 130/70 mmHg, increasing to 160/98 mmHg after 1 L of saline, with a JVP at 8 cm. There was generalized muscle weakness. Potassium 3.7 1.7 3.5 meq/L 7.47 Creatinine 2.8 2.9 2.3 mg/dL Magnesium 1.3 1.6 2.4 mg/dL Albumin 3.4 2.8 2.3 Total bilirubin 0.65 5.19 5.5"
        },
        {
            "id": "InternalMed_Harrison_3665",
            "title": "InternalMed_Harrison",
            "content": "Potassium 3.7 1.7 3.5 meq/L 7.47 Creatinine 2.8 2.9 2.3 mg/dL Magnesium 1.3 1.6 2.4 mg/dL Albumin 3.4 2.8 2.3 Total bilirubin 0.65 5.19 5.5 Abbreviations: ACTH, adrenocorticotropic hormone; HD2, hospital day 2; PTA, prior to admission. The patient\u2019s hospital course was complicated by acute respiratory failure attributed to pulmonary embolism; he died 2 weeks after admission. Why was this patient hypokalemic? Why was he weak? Why did he have an alkalosis? This patient suffered from metastatic small-cell lung cancer, which was persistent despite several rounds of chemotherapy and radiotherapy. He presented with profound hypokalemia, alkalosis, hypertension, severe weakness, jaundice, and worsening liver function tests."
        },
        {
            "id": "InternalMed_Harrison_3641",
            "title": "InternalMed_Harrison",
            "content": "A 76-year-old woman presented with a several-month history of diarrhea, with marked worsening over the 2\u20133 weeks before admission (up to 12 stools a day). Review of systems was negative for fever, orthostatic dizziness, nausea and vomiting, or headache. Past medical history included hypertension, kidney stones, and hypercholesterolemia; medications included atenolol, spironolactone, and lovastatin. She also reliably consumed >2 L of liquid per day in management of the nephrolithiasis. The patient received 1 L of saline over the first 5 h of her hospital admission. On examination at hour 6, the heart rate was 72 sitting and 90 standing, and blood pressure was 105/50 mmHg lying and standing. Her jugular venous pressure (JVP) was indistinct with no peripheral edema. On abdominal examination, the patient had a slight increase in bowel sounds but a nontender abdomen and no organomegaly."
        },
        {
            "id": "InternalMed_Harrison_27967",
            "title": "InternalMed_Harrison",
            "content": "Laboratory Abnormalities and Diagnosis The laboratory features in HHS are summarized in Table 418-6. Most notable are the marked hyperglycemia (plasma glucose may be >55.5 mmol/L [1000 mg/dL]), hyperosmolality (>350 mosmol/L), and prerenal azotemia. The measured serum sodium may be normal or slightly low despite the marked hyperglycemia. The corrected serum sodium is usually increased (add 1.6 meq to measured sodium for each 5.6-mmol/L [100-mg/dL] rise in the serum glucose). In contrast to DKA, acidosis and ketonemia are absent or mild. A small anion-gap metabolic acidosis may be present secondary to increased lactic acid. Moderate ketonuria, if present, is secondary to starvation."
        },
        {
            "id": "InternalMed_Harrison_3628",
            "title": "InternalMed_Harrison",
            "content": "For this patient, the CeH2O was 2.5 L/d when initially evaluated, i.e., with urine Na+ and K+ concentrations of 34 and 5.2 meq/L, plasma Na+ concentration of 150 meq/L, and a urinary volume of 3.4 L. Therefore, the patient was given 2.5 L of D5W over the first 24 h to replace ongoing free water losses, along with 2.1 L of D5W to replace half his free water deficit. Daily random urine electrolytes and urinary volume measurement can be used to monitor CeH2O and adjust daily fluid administration in this manner, while following plasma Na+ concentration. Physicians often calculate the free water deficit to guide therapy of hypernatremia, providing half the deficit in the first 24 h. This approach can be adequate in patients who do not have significant ongoing losses of free water, e.g., with hypernatremia due to decreased free water intake. This case illustrates how free water requirements can be grossly underestimated in hypernatremic patients if ongoing, daily free water losses are not"
        },
        {
            "id": "InternalMed_Harrison_20993",
            "title": "InternalMed_Harrison",
            "content": "(Fig. 326-2) In addition to the usual treatment of acute MI (Chap. 295), initial therapy is aimed at maintaining adequate systemic and coronary perfusion by raising systemic BP with vasopressors and adjusting volume status to a level that ensures optimum LV filling pressure. There is interpatient variability, but the values that generally are associated with adequate perfusion are systolic BP ~90 mmHg or mean BP >60 mmHg and PCWP >20 mmHg. Hypoxemia and acidosis must be corrected; most patients require ventilatory support (see \u201cPulmonary Edema,\u201d below). Negative inotropic agents should be discontinued and the doses of renally cleared medications adjusted. Hyperglycemia should be controlled with insulin. Bradyarrhythmias may require transvenous pacing. Recurrent ventricular tachycardia or rapid atrial fibrillation may require immediate treatment (Chap. 276)."
        },
        {
            "id": "Surgery_Schwartz_9555",
            "title": "Surgery_Schwartz",
            "content": "classification relates to the present or past severity of acute pancreatitis, prediction is about the future and ultimate severity and outcome of the patient. Accurately predicting acute Brunicardi_Ch33_p1429-p1516.indd 144401/03/19 6:44 PM 1445PANCREASCHAPTER 33Table 33-7Ranson\u2019s prognostic signs of pancreatitisCriteria for acute pancreatitis not due to gallstonesAt admissionDuring the initial 48 h Age >55 y Hematocrit fall >10 points WBC >16,000/mm3 BUN elevation >5 mg/dL Blood glucose >200 mg/dL Serum calcium <8 mg/dL Serum LDH >350 IU/L Arterial PO2 <60 mmHg Serum AST >250 U/dL Base deficit >4 mEq/L Estimated fluid sequestration >6 LCriteria for acute gallstone pancreatitisAt admissionDuring the initial 48 h Age >70 y Hematocrit fall >10 points WBC >18,000/mm3 BUN elevation >2 mg/dL Blood glucose >220 mg/dL Serum calcium <8 mg/dL Serum LDH >400 IU/L Base deficit >5 mEq/L Serum AST >250 U/dL Estimated fluid sequestration >4 LNote: Fewer than three positive criteria predict"
        },
        {
            "id": "InternalMed_Harrison_27948",
            "title": "InternalMed_Harrison",
            "content": "The measured serum sodium is reduced as a consequence of the hyperglycemia (1.6-mmol/L [1.6-meq] reduction in serum sodium for each 5.6-mmol/L [100-mg/dL] rise in the serum glucose). A normal serum sodium in the setting of DKA indicates a more profound water deficit. In \u201cconventional\u201d units, the calculated serum osmolality (2 \u00d7 [serum sodium + serum potassium] + plasma glucose [mg/dL]/ 18 + BUN/2.8) is mildly to moderately elevated, although to a lesser degree than that found in HHS (see below)."
        },
        {
            "id": "InternalMed_Harrison_32553",
            "title": "InternalMed_Harrison",
            "content": "Abbreviations: P, plasma; RC, red cells; S, serum; WB, whole blood. Electrolytes Sodium 137\u2013145 mmol/L 137\u2013145 meq/L Potassium 2.7\u20133.9 mmol/L 2.7\u20133.9 meq/L Calcium 1.0\u20131.5 mmol/L 2.1\u20133.0 meq/L Magnesium 1.0\u20131.2 mmol/L 2.0\u20132.5 meq/L Chloride 116\u2013122 mmol/L 116\u2013122 meq/L CO2 content 20\u201324 mmol/L 20\u201324 meq/L PCO2 6\u20137 kPa 45\u201349 mmHg pH 7.31\u20137.34 Glucose 2.22\u20133.89 mmol/L 40\u201370 mg/dL Lactate 1\u20132 mmol/L 10\u201320 mg/dL Total protein: Lumbar 0.15\u20130.5 g/L 15\u201350 mg/dL Cisternal 0.15\u20130.25 g/L 15\u201325 mg/dL Ventricular 0.06\u20130.15 g/L 6\u201315 mg/dL Albumin 0.066\u20130.442 g/L 6.6\u201344.2 mg/dL IgG 0.009\u20130.057 g/L 0.9\u20135.7 mg/dL IgG indexb 0.29\u20130.59 Oligoclonal bands (OGB) <2 bands not present in matched serum sample"
        },
        {
            "id": "InternalMed_Harrison_7284",
            "title": "InternalMed_Harrison",
            "content": "is characterized by the occurrence of multiple macro-/microadenomas expressing insulin, and it is not clear how to distinguish this entity from insulinoma preoperatively. The most reliable test to diagnose insulinoma is a fast up to 72 h with serum glucose, C-peptide, proinsulin, and insulin measurements every 4\u20138 h. If at any point the patient becomes symptomatic or glucose levels are persistently below <2.2 mmol/L (40 mg/dL), the test should be terminated, and repeat samples for the above studies should be obtained before glucose is given. Some 70\u201380% of patients will develop hypoglycemia during the first 24 h, and 98% by 48 h. In nonobese normal subjects, serum insulin levels should decrease to <43 pmol/L (<6 \u00b5U/mL) when blood glucose decreases to <2.2 mmol/L (<40 mg/ dL) and the ratio of insulin to glucose is <0.3 (in mg/dL). In addition to having an insulin level >6 \u00b5U/mL when blood glucose is <40 mg/ dL, some investigators also require an elevated C-peptide and serum proinsulin"
        },
        {
            "id": "Pharmacology_Katzung_7061",
            "title": "Pharmacology_Katzung",
            "content": "A 53-year-old woman with a history of knee osteoarthritis, high cholesterol, type 2 diabetes, and hypertension presents with new onset of hot flashes and a question about a dietary supplement. She is obese (body mass index [BMI] 33), does not exercise, and spends a good portion of her work day in a seated position. She eats a low-sugar diet and regularly eats packaged frozen meals for dinner because she doesn\u2019t have time to cook regularly. Her most recent laboratory values include a low-density lipoprotein (LDL) cholesterol that is above goal at 160 mg/dL (goal < 100 mg/dL) and a hemo-globin A1c that is well controlled at 6%. Her blood pressure is high at 160/100 mm Hg. Her prescription medications include simvastatin, metformin, and benazepril. She also takes over-the-counter ibuprofen for occasional knee pain and a multivitamin supplement once daily. She has heard good things about natural products and asks you if taking a garlic supplement daily could help to bring her blood"
        },
        {
            "id": "Surgery_Schwartz_9556",
            "title": "Surgery_Schwartz",
            "content": "mg/dL Blood glucose >220 mg/dL Serum calcium <8 mg/dL Serum LDH >400 IU/L Base deficit >5 mEq/L Serum AST >250 U/dL Estimated fluid sequestration >4 LNote: Fewer than three positive criteria predict mild, uncomplicated disease, whereas more than six positive criteria predict severe disease with a mortality risk of 50%.Abbreviations: AST = aspartate transaminase; BUN = blood urea nitrogen; LDH = lactate dehydrogenase; PO2 = partial pressure of oxygen; WBC = white blood cell count.Data from Ranson JHC. Etiological and prognostic factors in human acute pancreatitis: a review. Am J Gastroenterol. 1982;77:633 and from Ranson JH, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974;139:69.pancreatitis severity is important in making triage decisions about whether a patient should be transferred to a tertiary hospital or an intensive care unit and in making decisions about fluid therapy and whether an ERCP is"
        },
        {
            "id": "Obstentrics_Williams_392",
            "title": "Obstentrics_Williams",
            "content": "Serum creatinine decreases during normal gestation; >0.8 mg/dL (> 72 \ufffdmol/L) creatinine already borderline; protein, amino acid, and glucose excretion all increase Serum bicarbonate decreased by 4-5 mEq/L; Pc02 decreased 10 mm Hg; a Pc02 of 40 mm Hg already represents CO2 retention 5 mEq/L) during normal gestation; increased placental metabolism of AVP may cause transient diabetes insipidus during pregnancy AVP = vasopressin; IVP = intravenous pyelography; Pc02= partial pressure carbon dioxide. Modified from Lindheimer, 2000. elevated GFR persists until term, even though renal plasma flow declines during late pregnancy. Primarily as a consequence of this elevated GFR, approximately 60 percent of nulliparas during the third trimester experience urinary frequency, and 80 percent experience nocturia (F rederice, 2013)."
        },
        {
            "id": "InternalMed_Harrison_27955",
            "title": "InternalMed_Harrison",
            "content": "6. Assess patient: What precipitated the episode (noncompliance, infection, trauma, pregnancy, infarction, cocaine)? Initiate appropriate workup for precipitating event (cultures, CXR, ECG). 7. Measure capillary glucose every 1\u20132 h; measure electrolytes (especially K+, bicarbonate, phosphate) and anion gap every 4 h for first 24 h. 8. Monitor blood pressure, pulse, respirations, mental status, fluid intake and output every 1\u20134 h. 9. Replace K+: 10 meq/h when plasma K+ <5.0\u20135.2 meq/L (or 20\u201330 meq/L of infusion fluid), ECG normal, urine flow and normal creatinine documented; administer 40\u201380 meq/h when plasma K+ <3.5 meq/L or if bicarbonate is given. If initial serum potassium is >5.2 mmol/L (5.2 meq/L), do not supplement K+ until the potassium is corrected. 10. See text about bicarbonate or phosphate supplementation. 11."
        },
        {
            "id": "InternalMed_Harrison_3618",
            "title": "InternalMed_Harrison",
            "content": "On physical examination, the patient was alert, extubated, and thirsty. Weight was 97.5 kg. Urine output for the previous 24 h had been 3.4 L, with an IV intake of 2 L/d of D5W. After 3 days of intravenous hydration, a water deprivation test was performed. A single dose of 2 \u03bcg IV desmopressin (DDAVP) was given at 9 h (+9): Why did the patient develop hypernatremia, polyuria, and acute renal insufficiency? What does the water deprivation test demonstrate? What is the underlying pathophysiology of this patient\u2019s hypernatremic syndrome?"
        },
        {
            "id": "InternalMed_Harrison_27919",
            "title": "InternalMed_Harrison",
            "content": "cHoice of initial GlucoSe-loWerinG aGent The level of hyperglycemia and the patient\u2019s individualized goal (see \u201cEstablishment of Target Level of Glycemic Control\u201d) should influence the initial choice of therapy. Assuming that maximal benefit of MNT and increased physical activity has been realized, patients with mild to moderate hyperglycemia (FPG <11.1\u201313.9 mmol/L [200\u2013250 mg/dL]) often respond well to a single, oral glucose-lowering agent. Patients with more severe hyperglycemia (FPG >13.9 mmol/L [250 mg/dL]) may respond partially but are unlikely to achieve normoglycemia with oral monotherapy. A stepwise approach that starts with a single agent and adds a second agent to achieve the glycemic target can be used (see \u201cCombination therapy with glucose-lowering agents,\u201d below). Insulin can be used as initial therapy in individuals with severe hyperglycemia (FPG <13.9\u201316.7 mmol/L [250\u2013300 mg/dL]) or in those who are symptomatic from the hyperglycemia. This approach is based on the"
        },
        {
            "id": "InternalMed_Harrison_3649",
            "title": "InternalMed_Harrison",
            "content": "Creatinine (mg/dL) 1.2 2.35 2.10 2.02 1.97 1.79 1.53 1.20 1.13 days after DDAVP administration. It is 64e-6 conceivable that residual hypovolemic hyponatremia attenuated the recovery of the plasma Na+ concentration. Alternatively, attenuated recovery was due to persistent effects of the single dose of DDAVP. Of note, although the plasma half-life of DDAVP is only 1\u20132 h, pharmacodynamic studies indicate a much more prolonged effect on urine output and/or urine osmolality. One final consideration is the effect of the patient\u2019s initial renal dysfunction on the pharmacokinetics and pharmacodynamics of the administered DDAVP, which is renally excreted; DDAVP should be administered with caution for the reinduction of hyponatremia in patients with chronic kidney disease or acute renal dysfunction. A 44-year-old woman was referred from a local hospital after presenting with flaccid paralysis. Severe hypokalemia was documented (2.0 meq/L), and an infusion containing KCl was initiated."
        }
    ],
    "scores": [
        0.030524286844270013,
        0.028418640183346066,
        0.028133903133903133,
        0.027892058799692185,
        0.02635452518561811,
        0.026253593101245608,
        0.025302294830975867,
        0.025108077913246225,
        0.024910714658233236,
        0.02407010516946572,
        0.022851314438819006,
        0.021147044820784874,
        0.018524871355060035,
        0.017857142857142856,
        0.017837323608688758,
        0.017711598746081504,
        0.01676094699350513,
        0.01655982905982906,
        0.01633333333333333,
        0.01568010713923675,
        0.015259813932380304,
        0.015220189133232611,
        0.014953478068232167,
        0.01472213847854487,
        0.014190821256038648,
        0.013480392156862746,
        0.013469921534437664,
        0.013432165318957773,
        0.013347873500545256,
        0.013340965128566397,
        0.01329225352112676,
        0.013160093582887701
    ]
}